Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for CVRx in a research report issued on Wednesday, ...

The main disadvantage of haloperidol is the potential for extrapyramidal symptoms (EPS), including an agitated physical response (akathisia). However, alternating doses of lorazepam with ...

Background: Second-generation antipsychotics (SGAs) are thought to have a lower likelihood of inducing extrapyramidal symptoms (EPS) than are first-generation antipsychotics (FGAs). Clinical ...

And based on my projections, EPS could hit $1.40 ... and fatigue - all symptoms associated with the "cortisol withdrawal" many patients experience following surgery or start of medical therapy ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

The cost of cocoa reached a record high in December 2024, and the price keeps climbing. How is industry reacting and what ...